US Pharma MarketingASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP2 agents in triple-negative breast cancer.
Source: FierceBiotech